Symbiotec Pharmalab LimitedSYMBIOTECNSE
Symbiotec’s Q1 consolidated PAT falls 53% as new businesses add costs
As filed · Symbiotec Pharmalab Limited has informed the Exchange regarding a press release dated September 21, 2026, titled "Investor Release of Financial Results for the 1st Quarter ended June 30, 2026".
EarningsMixedNotablemateriality 65 out of 100
What happened
FactSymbiotec reported Q1FY27 consolidated revenue of Rs. 218.2 crore, up from Rs. 203.2 crore in Q1FY26, while consolidated EBIDTA declined to Rs. 45.2 crore from Rs. 58.0 crore and PAT fell to Rs. 14.1 crore from Rs. 29.9 crore. The company attributed the drag to Rs. 23 crore of operating expenses and Rs. 12 crore of depreciation from new businesses that are not yet generating revenue; it expects revenue from various new businesses to begin in the next 6–12 months.